IL31

(redirected from Interleukin-31)

IL31

A gene on chromosome 12q24.31 that encodes interleukin-31, an immunomodulatory cytokine which activates STAT3, and possibly STAT1 and STAT5, through the IL31 receptor, which is composed of a heterodimer of IL31RA and OSMR. IL31 may play a role in skin immunity.
References in periodicals archive ?
KPL-716 is an investigational fully-human monoclonal antibody that targets OSMR, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis.
* Kindred Biosciences, Inc.(NASDAQ: KIN) rose 21.2% to $8.15 in pre-market trading after reporting results from pilot field effectiveness study of its Interleukin-31 monoclonal antibody for the treatment of atopic dermatitis in dogs.
Drugs in development for AD include nemolizumab (a humanized monoclonal antibody that inhibits interleukin-31 signaling), upadacitinib (a JAK1 selective inhibitor), baricitinib (an oral JAK1 / 2 inhibitor), and topical tapinarof (an agonist of the aryl hydrocarbon receptor).
Kiniksa announced that it presented clinical and preclinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta, or OSMRss, the shared receptor subunit for interleukin-31, or IL-31, and oncostatin M, or OSM signaling.
Mishra and his team looked at a protein, or cytokine, called interleukin-31 (IL-31), which is overproduced in patients with atopic dermatitis and is involved in triggering itch response.
Interleukin-31 (IL-31) is mainly produced by the activated T helper type 2 cells as well as other types of cells, including monocytes, macrophages, and immature and mature dendritic and mast cells [5-7].
Most gp130/IL-6 cytokines have a long-chain (20-30 amino acids): contrarily, interleukin-31 has two long helices (A and D, with 25-28 amino acid) and two short helices (B and C, with 10-16 amino acids) [14, 15].
According to the company, CYTOPOINT is a ready-to-use, sterile liquid injectable containing a mAb specifically designed to target and neutralize cytokine interleukin-31 (IL-31), a key cytokine (protein important in cell-to-cell communication) involved in triggering the itch associated with canine atopic dermatitis.
The trial is designed to identify chronic pruritic conditions where interleukin-31 and/or oncostatin M may be playing a role and to investigate the efficacy, safety and tolerability of KPL-716 in reducing the moderate-to-severe pruritus experienced by these subjects.
Drugs in development for AD include nemolizumab (a humanized monoclonal antibody that inhibits interleukin-31 signaling), upadacitinib (aJAKl selective inhibitor), baricitinib (an oral JAKl/2 inhibitor), and topical tapinarof (an agonist of the aryl hydrocarbon receptor).
Interleukin-31 (IL-31) is a novelly detected proinflammatory cytokine belonging to gp130/IL-6 cytokine family which includes IL-6, IL-11, IL-27, oncostatin M, cardiotrophin-1, cardiotrophin-like cytokine, and leukemia inhibitory factor [10, 11].